Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU) Short Interest Down 99.9% in August

Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU) was the target of a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 1 shares, a decline of 99.9% from the July 30th total of 884 shares. Based on an average daily trading volume, of 143 shares, the short-interest ratio is presently 0.0 days.

Drugs Made in America Acquisition Price Performance

Shares of DMAAU opened at $10.79 on Wednesday. The stock has a 50-day moving average of $10.80 and a two-hundred day moving average of $10.70. Drugs Made in America Acquisition has a one year low of $10.30 and a one year high of $12.50.

Drugs Made in America Acquisition Company Profile

Drugs Made in America Acquisition Corp is a special purpose acquisition company incorporated in Delaware and traded on the NASDAQ under the ticker DMAAU. It was organized to raise capital through its initial public offering and to identify and complete a business combination with one or more U.S.-based pharmaceutical or biotechnology companies.

The company’s investment mandate is focused on target businesses engaged in the development, manufacture or commercialization of finished dosage pharmaceuticals, active pharmaceutical ingredients and related medical products for the American market.